T1	Participants 136 158	advanced breast cancer
T2	Participants 161 262	A prospective multicenter trial was conducted in 155 consecutive patients with Stage IV breast cancer
T3	Participants 1045 1091	In patients with more than one metastatic site
T4	Participants 1570 1718	estrogen receptor (ER)-negative patients, for patients younger than 51 years of age, and for patients with a disease-free interval of 1 year or less
T5	Participants 1720 1789	Patients with these parameters probably belong to the same population
